secwatch.observer — SEC 8-K summary
======================================

Issuer:     uniQure N.V. (QURE)
CIK:        0001590560
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001104659-23-115011
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

uniQure Q3 net loss widens to $89.6M ($1.88/sh); cash at $659M
--------------------------------------------------------------

- Net loss of $89.6M ($1.88 diluted EPS) vs $47.9M ($1.02 EPS) in Q3 2022; revenue flat at $1.4M.
- Cash and investments $658.9M as of Sept 30, 2023; $180M cost savings expected to fund ops into Q2 2027.
- FDA cleared IND for AMT-260 (epilepsy); AMT-130 (Huntington's) update expected later Q4 2023.
- Strategic reorganization: 28% workforce cut, CSO Ricardo Dolmetsch departs, Richard Porter becomes Chief Business & Scientific Officer.
- Received $100M milestone from CSL for first U.S. HEMGENIX sale; won 2023 Prix Galien USA Award.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590560/000110465923115011/0001104659-23-115011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590560/000110465923115011/tm2330023d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-115011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer